Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens
Christian Cadeddu Dessalvi(University of Cagliari), Giuseppe Mercuro(University of Cagliari), Alessia Pepe(Fondazione Toscana Gabriele Monasterio), Alessia Gimelli(Fondazione Toscana Gabriele Monasterio), Javid J. Moslehi(University of California, San Francisco), Rudolf A. de Boer(University Medical Center Groningen), Cinzia Nugara(University of Palermo), Ines Monte(University of Catania), Concetta Zito(University of Messina), Carlo G. Tocchetti(Federico II University Hospital), Alexander R. Lyon(Royal Brompton Hospital), Cláudia Penna(University of Turin), Rosalinda Madonna(University of Chieti-Pescara), Giuseppina Novo(AOL (United States)), Donato Mele(University of Ferrara)
Cited by 55
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k